Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.07 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in loop of henle epithelial cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 2 Parkinson's papers of 985 | 0.85 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 3636
Sealed predictions
- CDR2 in dopamine neurons, braak+0.54 (p 0.133) → -0.08 (p 0.840)receipt 3645
Swarm cases
receipt 3645: CDR2 in dopamine neurons, braak
- power
- full sample +0.26 (p 0.294, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.17 (p 0.509, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.18 (p 0.476, n 18). could be the mix.
- skeptic
- leave-one-out range +0.16 to +0.40, sign flips 0; without severely affected donors +0.26 (p 0.294, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CDR2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts